Studying Heart Muscle Weakness Caused by Irregular Heartbeat
Collects existing data from adults suspected of having arrhythmia-induced cardiomyopathy at Basel.
Plain-language title generated from the registry record
Registry title: Characterization of Arrhythmia-induced Cardiomyopathy
Key facts
- Where
- Basel, SwitzerlandSee the site
Where in Switzerland
- University Hospital Basel, Department of CardiologyBasel, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Basel, Switzerland
- Trial code
- NCT05662293
- Record updated
- 4 March 2025
- Original description
The goal of the this observational study is to gather clinically available data on patients presenting with a suspicion for arrhythmia-induced cardiomyopathy (AiCM) at the University Hospital Basel.Read full original descriptionShow less
Arrhythmia-induced Cardiomyopathy - a Prospective Observational Cohort Study
The goal of the this observational study is to gather clinically available data on patients presenting with a suspicion for arrhythmia-induced cardiomyopathy (AiCM) at the University Hospital Basel.
Inclusion: Diagnostic or suspicion of AiCM as presence of specified keyword in patient's file or as screened by colleagues of the internal medicine or cardiology clinics; Signed study consent; Patients with a reduced left-ventricular ejection fraction (LVEF ≤50%) or a reduction of 15% in the ejection fraction (EF) between two echocardiographies and a concomitant diagnosis of any arrhythmia likely to lead to AiCM within one year before or after diagnosis of the reduced LVEF from 2010-2021.
Exclusion: Temporary exclusion criteria: Acute health condition such as myocardial infarction, patients presenting with a major trauma, a sepsis, patients shortly after cardiac surgery, and patients in shock (>100 bpm, <90 systolic BP, evidence of organ dysfunction); Life expectancy <1 year (palliative, terminal cancer); Retrospective part; Patients with life expectancy <1 year (palliative, terminal cancer); Acute event clearly leading to an acutely reduced LVEF (massive type I myocardial infarction, cardiogenic shock from a coronary or myocardial etiology, septic shock leading to toxic myopathy, hypovolemic shock with reduced EF, cardiac arrest and/or need for resuscitation); Age <18 years old; Age < 18 years old; Patient's active refusal of the general consent of the University Hospital Basel; Patient's active refusal of the general consent of the University Hospital Basel.
Prospective part.